Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients

Francis Nissen , Marc Humbert , Peter Gibson , Konstantinos Kostikas , Xavier Jaumont , Petter Olsson , Luisa Alvares , Jean Bousquet


Background: The efficacy of omalizumab on patient-reported outcomes (PROs) in severe allergic asthma has been reported in several randomized controlled trials. This systematic literature review aimed to summarize the effectiveness of omalizumab on PROs in real-world settings

Methods: The literature search was performed using PubMed, EMBASE, and Cochrane databases. It included studies using Global Evaluation of Treatment Effectiveness (GETE), Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Test (ACT), and Asthma Control Questionnaire (ACQ) comparing 16 weeks, 6 months, 12 months, and end of the study post-treatment outcomes with baseline observations in patients with severe allergic asthma

Results: In total, 85 studies were included in this systematic review. GETE scores were consistently good or excellent in 53%–100% of patients receiving omalizumab across time points compared with baseline. Omalizumab treatment also improved health-related quality of life (HRQoL) and asthma control scores at all time points (Table). At the end of the studies, the proportion of participants who achieved minimal clinically important differences (MCID) for ACT (≥3), ACQ (≥0.5), and AQLQ (≥0.5) ranges from 50%–62%, 60%–95% and 72%–100%, respectively

Conclusion: Omalizumab treatment consistently improves asthma-related HRQoL (AQLQ), asthma control (ACQ, ACT), physicians’/patients’ GETE in real-world treatment of severe allergic asthma

More Publications

Omalizumab for IgE-mediated food allergy: A systematic review and meta-analysis

Zuberbier T , Wood RA , Bindslev-Jensen C , Fiocchi A , Chinthrajah S , Worm M , Deschildre A , Rivas MF , Santos A , Jaumont JX , Tassinari P

Dec, 2022

The Journal of Allergy and Clinical Immunology: In Practice

Efficacy and safety of bisoprolol compared to other selective beta-1 blockers in the treatment of hypertension: a systematic review and meta-analysis of randomized parallel clinical trials

U Jadhav , T Nair , S Bansal , S Ray

Oct, 2021

European Heart Journal

Effect of omalizumab on glucocorticoid use and lung function in the treatment of allergic bronchopulmonary aspergillosis in people with cystic fibrosis: a systematic review and meta-analysis

Meiling Jin , Jo A. Douglass , J. Stuart Elborn , Slawomir Lazarewicz , Xavier Jaumont , Meng Yan , Ritesh Agarwal, , William J. Calhoun,

Dec, 2022

The Journal of Allergy and Clinical Immunology